Medtronic/$MDT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Medtronic
One of the largest medical-device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, transcatheter heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company primarily markets its products to healthcare institutions and physicians in the United States, Western Europe, and Japan. Foreign sales account for roughly 50% of the company's total sales.
Ticker
$MDT
Sector
Primary listing
NYSE
Industry
Health Care Equipment & Supplies
Headquarters
Galway, Ireland
Employees
95,000
ISIN
IE00BTN1Y115
Website
Medtronic Metrics
BasicAdvanced
$110B
23.83
$3.61
0.81
$2.80
3.30%
Price and volume
Market cap
$110B
Beta
0.81
52-week high
$96.25
52-week low
$75.96
Average daily volume
8.9M
Dividend rate
$2.80
Financial strength
Current ratio
1.849
Quick ratio
1.202
Long term debt to equity
55.04
Total debt to equity
61.393
Dividend payout ratio (TTM)
76.98%
Interest coverage (TTM)
9.19%
Profitability
EBITDA (TTM)
9,560
Gross margin (TTM)
65.39%
Net profit margin (TTM)
13.90%
Operating margin (TTM)
19.09%
Effective tax rate (TTM)
16.63%
Revenue per employee (TTM)
$350,000
Management effectiveness
Return on assets (TTM)
4.41%
Return on equity (TTM)
9.51%
Valuation
Price to earnings (TTM)
23.828
Price to revenue (TTM)
3.297
Price to book
2.3
Price to tangible book (TTM)
-20.5
Price to free cash flow (TTM)
21.328
Free cash flow yield (TTM)
4.69%
Free cash flow per share (TTM)
403.31%
Dividend yield (TTM)
3.26%
Forward dividend yield
3.30%
Growth
Revenue change (TTM)
3.62%
Earnings per share change (TTM)
30.80%
3-year revenue growth (CAGR)
1.91%
10-year revenue growth (CAGR)
5.17%
3-year earnings per share growth (CAGR)
-1.08%
10-year earnings per share growth (CAGR)
4.12%
3-year dividend per share growth (CAGR)
3.57%
10-year dividend per share growth (CAGR)
8.66%
What the Analysts think about Medtronic
Analyst ratings (Buy, Hold, Sell) for Medtronic stock.
Bulls say / Bears say
Medtronic's diabetes segment experienced an 8.4% sales increase in Q3 2025, driven by strong adoption of its insulin delivery systems, contributing to higher-than-expected profits. (reuters.com)
The company received FDA approval for the world's first adaptive deep brain stimulation system for Parkinson's patients, marking a significant advancement in personalized, sensing-enabled care. (prnewswire.com)
Medtronic announced plans to separate its diabetes business into a standalone company, aiming to unlock value and allow focused growth in this high-demand sector. (reuters.com)
Medtronic's medical surgical unit saw a 1.9% decline in sales to $2.07 billion in Q3 2025, missing estimates due to changed buying patterns and competitive pressures in the surgical staplers market. (reuters.com)
Analysts have recently lowered their price targets for Medtronic, with RBC Capital reducing its target to $101 from $105, indicating tempered expectations for the stock's performance. (markets.businessinsider.com)
The company's net income decreased by 2.12% year-over-year in Q3 2025, reflecting potential challenges in maintaining profitability amid operational pressures. (google.com)
Data summarised monthly by Lightyear AI. Last updated on 21 Jun 2025.
Medtronic Financial Performance
Revenues and expenses
Medtronic Earnings Performance
Company profitability
Medtronic News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
Jul11
Medtronic
Dividend·Payment
$0.71Per share
FAQs
What’s the current market cap for Medtronic stock?
Medtronic (MDT) has a market cap of $110B as of July 01, 2025.
What is the P/E ratio for Medtronic stock?
The price to earnings (P/E) ratio for Medtronic (MDT) stock is 23.83 as of July 01, 2025.
Does Medtronic stock pay dividends?
Yes, the Medtronic (MDT) stock pays dividends to shareholders. As of July 01, 2025, the dividend rate is $2.8 and the yield is 3.3%. Medtronic has a payout ratio of 76.98% on a trailing twelve-month basis.
When is the next Medtronic dividend payment date?
The next Medtronic (MDT) dividend payment is scheduled for July 11, 2025.
What is the beta indicator for Medtronic?
Medtronic (MDT) has a beta rating of 0.81. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.